🇺🇸 FDA
Pipeline program

training kit, CHF1535 pMDI 100/6, CHF5993 pMDI-US

CLI-05993AA3-06

Phase 3 small_molecule active

Quick answer

training kit, CHF1535 pMDI 100/6, CHF5993 pMDI-US for Chronic obstructive pulmonary disease (COPD) is a Phase 3 program (small_molecule) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).

Program details

Company
Chiesi Farmaceutici S.p.A
Indication
Chronic obstructive pulmonary disease (COPD)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials